[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE3865817D1 - - Google Patents

Info

Publication number
DE3865817D1
DE3865817D1 DE88119863T DE3865817T DE3865817D1 DE 3865817 D1 DE3865817 D1 DE 3865817D1 DE 88119863 T DE88119863 T DE 88119863T DE 3865817 T DE3865817 T DE 3865817T DE 3865817 D1 DE3865817 D1 DE 3865817D1
Authority
DE
Germany
Prior art keywords
cycloserine
cognitive
compound
enhancing activity
prodrug compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE88119863T
Other languages
English (en)
Inventor
Alex A. St.Louis Missouri 63146 Us Cordi
Gail E. Chesterfield Missouri 63017 Us Handelmann
Joseph B. Black Jack Missouri 63033 Us Monahan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Application granted granted Critical
Publication of DE3865817D1 publication Critical patent/DE3865817D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE88119863T 1987-12-01 1988-11-29 Expired - Fee Related DE3865817D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/127,121 US4904681A (en) 1987-12-01 1987-12-01 D-cycloserine and its prodrugs as cognitive enhancers

Publications (1)

Publication Number Publication Date
DE3865817D1 true DE3865817D1 (de) 1991-11-28

Family

ID=22428413

Family Applications (1)

Application Number Title Priority Date Filing Date
DE88119863T Expired - Fee Related DE3865817D1 (de) 1987-12-01 1988-11-29

Country Status (20)

Country Link
US (1) US4904681A (de)
EP (2) EP0319824B1 (de)
JP (2) JPH0621065B2 (de)
KR (1) KR0134198B1 (de)
AT (1) ATE68698T1 (de)
AU (4) AU622630B2 (de)
CA (1) CA1328617C (de)
DE (1) DE3865817D1 (de)
DK (1) DK173589B1 (de)
ES (1) ES2040314T3 (de)
FI (1) FI885559A0 (de)
GR (1) GR3003571T3 (de)
IE (1) IE61825B1 (de)
IL (1) IL88531A (de)
NO (1) NO885337D0 (de)
NZ (1) NZ227131A (de)
PH (1) PH26467A (de)
PT (1) PT89109B (de)
WO (1) WO1989005144A1 (de)
ZA (1) ZA888981B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187171A (en) * 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US5061721A (en) * 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5260324A (en) * 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5066665A (en) * 1990-05-21 1991-11-19 Warner-Lambert Co. Substituted isoxazolidin-3-ones and derivatives thereof acting at muscarinic receptors
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
NZ260302A (en) * 1994-04-13 1996-05-28 New Zealand Meat Ind Res Inst Treating bait aversion by including substances which disrupt the associative learning process into bait compositions
AU4128896A (en) * 1994-11-23 1996-06-17 G.D. Searle & Co. Use of amino-isoxazolidone compounds for treatment of memory impairment following traumatic brain injury
AU4019395A (en) 1994-11-23 1996-06-17 G.D. Searle & Co. Use of amino-isoxazolidone compounds for improvement of implicit memory
ATE204852T1 (de) * 1995-02-15 2001-09-15 Bearsden Bio Inc Alkylcarboxy-aminosäure modulatoren für den kainat-rezeptor
US6361957B1 (en) * 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
WO1997020553A1 (en) * 1995-12-07 1997-06-12 Javitt Daniel C Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists
US6355681B2 (en) * 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
FR2742748B1 (fr) * 1995-12-21 1998-01-30 Adir Nouveau derive de 4-imidazolidinone, son procede de preparation et les compositions pharmaceutiques qui le contiennent
KR100396114B1 (ko) * 1996-10-31 2003-11-20 동아제약 주식회사 D-시클로세린의 제조방법
PT1073432E (pt) 1998-04-14 2007-10-22 Gen Hospital Corp Utilização da d-alanina ou da d-serina para o tratamento da esquizofrenia
JP3363440B2 (ja) * 1998-06-10 2003-01-08 明治製菓株式会社 脊髄小脳変性症治療剤および脊髄小脳変性症治療用組成物
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
CA2442330A1 (en) * 2001-03-29 2002-10-10 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US20060252761A1 (en) * 2001-03-29 2006-11-09 Michael Davis Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine
KR20040016849A (ko) 2001-04-02 2004-02-25 파노라마 리서치, 인크. 치료제로 사용되는 항산화제 니트로옥사이드 및 니트론류
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
MXPA05012493A (es) * 2003-05-27 2006-05-25 Forest Laboratories Combinacion de un antagonista del receptor de nmda y un inhibidor selectivo de reabsorcion de serotonina para el tratamiento de depresion y otros trastornos de estado de animo.
EP1660634A4 (de) * 2003-08-08 2009-02-18 Burnham Inst P16-vermittelte regulation von nmda-rezeptoren
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
AU2006244297A1 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of CNS disorders
CN102186883B (zh) 2008-09-18 2016-08-03 西北大学 Nmda受体调节剂和其用途
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
JP5928828B2 (ja) 2010-02-11 2016-06-01 ノースウエスタン ユニバーシティ Ｎｍｄａ受容体モジュレータを安定化させる二次構造及びその使用
KR102410989B1 (ko) 2013-01-29 2022-06-17 앱티닉스 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
ES2935352T3 (es) 2013-01-29 2023-03-06 Aptinyx Inc Moduladores de receptores NMDA de espiro-lactama y sus usos
JP2016506962A (ja) 2013-01-29 2016-03-07 ノーレックス, インコーポレイテッドNaurex, Inc. スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
WO2014120786A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN105026401A (zh) 2013-01-29 2015-11-04 诺雷克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
KR102128675B1 (ko) 2016-05-19 2020-06-30 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
IL264496B (en) 2016-08-01 2022-09-01 Aptinyx Inc Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
CN109906218B (zh) 2016-08-01 2023-01-17 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
EA201990428A1 (ru) 2016-08-01 2019-08-30 Аптиникс Инк. Спиролактамовые модуляторы nmda-рецептора и их применение
JP2019527232A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタムｎｍｄａ修飾因子及びこれを用いた方法
PE20190503A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
EP3427729A1 (de) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid zur behandlung von epileptischen erkrankungen, störungen oder zuständen
WO2019152687A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3010599A1 (de) * 1979-03-22 1980-10-09 Continental Pharma Derivate von glycinamid, deren herstellung und verwendung

Also Published As

Publication number Publication date
FI885559A0 (fi) 1988-11-30
NO885337D0 (no) 1988-11-30
ES2040314T3 (es) 1995-04-01
EP0319824B1 (de) 1991-10-23
US4904681A (en) 1990-02-27
PH26467A (en) 1992-07-27
KR0134198B1 (ko) 1998-04-21
IL88531A0 (en) 1989-06-30
PT89109A (pt) 1989-12-29
AU7746794A (en) 1995-01-05
WO1989005144A1 (en) 1989-06-15
ATE68698T1 (de) 1991-11-15
IL88531A (en) 1993-02-21
AU622630B2 (en) 1992-04-16
EP0421997A1 (de) 1991-04-17
AU1083992A (en) 1992-05-07
NZ227131A (en) 1991-09-25
PT89109B (pt) 1993-07-30
IE61825B1 (en) 1994-11-30
DK669088D0 (da) 1988-11-30
JPH01193220A (ja) 1989-08-03
ZA888981B (en) 1990-01-31
AU2813089A (en) 1989-07-05
EP0319824A1 (de) 1989-06-14
DK173589B1 (da) 2001-04-02
JPH0621065B2 (ja) 1994-03-23
CA1328617C (en) 1994-04-19
AU2631988A (en) 1989-06-01
KR890009392A (ko) 1989-08-01
JPH05201859A (ja) 1993-08-10
GR3003571T3 (de) 1993-03-16
DK669088A (da) 1989-06-02
IE883567L (en) 1989-06-01

Similar Documents

Publication Publication Date Title
DE3865817D1 (de)
DE3779053D1 (de)
EG18729A (en) Compound of n- amino - 1,2,4-triazinones used as insecticide.
AU1255488A (en) Phenyl carbamate
AU1510488A (en) Novel compounds
AU1767588A (en) Novel compounds
GR3004959T3 (de)
PH25095A (en) Beta-alkylmelatonins
PH30818A (en) Novel substituted thienopyrans as antihpertensive agents.
EP0405905A3 (en) Use of isoxazolin-3-one derivatives as antidepressants
JPS6447781A (en) Novel compound
AU2707188A (en) Novel compounds
FR2611460B1 (fr) Perfectionneme nts aux etageres
AU2011388A (en) N-phenyl compounds
FR2621212B1 (fr) Perfectionnement aux roues de plombage des semoirs
JPS6422877A (en) Novel compound
IE870012L (en) Polyfluoroalkylthiomethyl compounds.
IE870360L (en) Cyanoethanimidamido compounds.
IE871904L (en) Benzenesulphonamidoindanyl compounds.
ZA888675B (en) 1,4-disubstituted-piperidinyl compounds
AU603352C (en) Benzoheterocyclic compounds
FR2627937B2 (fr) Perfectionnement aux roues de plombage des semoirs
IE873445L (en) Herbicidal composition.
GB8708191D0 (en) Antimicrobial compounds
GB8725726D0 (en) Antimicrobial compounds

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee